Transplant Infectious Disease最新文献

Posttransplant HBV Vaccine Compliance, Seroprotection, and Kinetics of Hepatitis B Surface Antibody in Thoracic Organ Transplant Recipients.

IF 2.6 4区医学

Transplant Infectious Disease Pub Date : 2025-02-24 DOI: 10.1111/tid.70015

Chia-Yu Chiu, Priya Sampathkumar, Lisa M Brumble, Holenarasipur R Vikram, Kymberly D Watt, Elena Beam

{"title":"Posttransplant HBV Vaccine Compliance, Seroprotection, and Kinetics of Hepatitis B Surface Antibody in Thoracic Organ Transplant Recipients.","authors":"Chia-Yu Chiu, Priya Sampathkumar, Lisa M Brumble, Holenarasipur R Vikram, Kymberly D Watt, Elena Beam","doi":"10.1111/tid.70015","DOIUrl":"https://doi.org/10.1111/tid.70015","url":null,"abstract":"Introduction: Vaccination is crucial to the thoracic solid organ transplant (SOT) population to reduce vaccine-preventable infection. However, data on posttransplant hepatitis B virus (HBV) vaccination compliance and vaccine-induced seroprotection are lacking.Methods: We conducted a retrospective study of adult thoracic organ (heart and lung) transplant recipients at Mayo Clinic sites in Minnesota, Arizona, and Florida between January 2018 and August 2023. Recombivax HB was used before 2020, and Heplisav-B was preferred after 2020. Recipients with posttransplant hepatitis B surface antibody (HBsAb) < 10 IU/L were eligible for the HBV vaccine. HBV seroprotection was defined as an HBsAb ≥ 10 IU/L.Results: A total of 1116 recipients were evaluated, all of whom underwent posttransplant HBsAb testing. Of these, 751 (67%) had an HBsAb level < 10 IU/L and were eligible for posttransplant HBV vaccination. Of the eligible recipients, 117 (16%) completed the HBV vaccine series during the study period. Among these 117 recipients, 40 (34%) had their HBsAb levels rechecked after completing the vaccine series, with a seroprotection rate of 37.5% (15/40). There was no statistically significant difference in the seroprotection rates between Heplisav-B and Recombivax HB vaccines (39% [13/33] vs. 29% [2/7]; p = 0.691). In addition, HBsAb levels were lowest at week 2 but rebounded at week 4 posttransplant and pretransplant HBsAb levels of ≥100 IU/L ensured 5-year seroprotection.Conclusion: Suboptimal compliance with HBV vaccination and poor vaccine-induced seroprotection occur in thoracic organ transplant recipients, regardless of the vaccine used. These findings underscore the necessity of enhancing vaccination strategies for SOT recipients.","PeriodicalId":23318,"journal":{"name":"Transplant Infectious Disease","volume":" ","pages":"e70015"},"PeriodicalIF":2.6,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143493915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Safety of Once-Weekly Dapsone for Pneumocystis jirovecii Pneumonia Prophylaxis in Kidney Transplant Recipients. 肾移植受者每周一次使用达哌酮预防肺孢子虫肺炎的安全性

IF 2.6 4区医学

Transplant Infectious Disease Pub Date : 2025-02-24 DOI: 10.1111/tid.70012

Lauren Schumacher, Olivia Philippart, Abbey Carr, Catherine J Cj Sadler, Sravanthi Paluri

{"title":"Safety of Once-Weekly Dapsone for Pneumocystis jirovecii Pneumonia Prophylaxis in Kidney Transplant Recipients.","authors":"Lauren Schumacher, Olivia Philippart, Abbey Carr, Catherine J Cj Sadler, Sravanthi Paluri","doi":"10.1111/tid.70012","DOIUrl":"https://doi.org/10.1111/tid.70012","url":null,"abstract":"Background: Sulfamethoxazole-trimethoprim (SMX-TMP) is recommended first-line for Pneumocystis jirovecii pneumonia (PJP) prophylaxis in kidney transplant recipients. In cases of sulfa allergy or intolerance, our center utilizes dapsone 100 mg once weekly as alternative prophylaxis. As both agents have the potential to cause hematologic abnormalities, we sought to compare hematologic effect profiles of weekly dapsone versus SMX-TMP in kidney transplant recipients.Methods: This retrospective, single-center, cohort study included kidney transplant recipients who received SMX-TMP or dapsone for PJP prophylaxis. The primary endpoint was the change in hemoglobin from baseline to nadir. Secondary endpoints included hemoglobin and white blood cell (WBC) count at 1, 3, and 6 months posttransplant, time to hemoglobin nadir, neutropenia incidence, and ANC nadir. In addition, we evaluated the incidence of hospital readmission, bacteremia, and PJP.Results: A total of 509 kidney transplant recipients were included (334 SMX-TMP vs. 175 dapsone). Median decrease in hemoglobin (g/dL) from baseline to nadir was greater in the dapsone group (0 SMX-TMP vs. -0.20 dapsone; p = 0.046). Mean absolute hemoglobin count was lower in the dapsone group at all time points. There was no difference in WBC, ANC nadir, or incidence of neutropenia at any time point between groups. Greater frequencies in readmissions (30.7% vs. 55.7%; p < 0.001) and bacteremia (3.6% vs. 10.8%; p < 0.001) were observed in the dapsone arm.Conclusions: Once-weekly dapsone is associated with statistically significant decreases in hemoglobin when compared to SMX-TMP in a kidney transplant cohort, which may be clinically relevant in select patients. Dapsone use may also increase infection risk.","PeriodicalId":23318,"journal":{"name":"Transplant Infectious Disease","volume":" ","pages":"e70012"},"PeriodicalIF":2.6,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143493919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Addressing the Rising Burden of Carbapenemase-Producing Enterobacterales in Liver Transplant Recipients: A Call for Enhanced Surveillance and Prevention Strategies.

IF 2.6 4区医学

Transplant Infectious Disease Pub Date : 2025-02-24 DOI: 10.1111/tid.70014

Muna A Al-Maslamani, Javed Iqbal

引用次数: 0

Lessons From the Utilization of Hepatitis B Virus Nucleic Acid Test Positive Donors for Hepatitis B Vaccinated Lung Transplant Candidates (INHIBITOR) Study.

IF 2.6 4区医学

Transplant Infectious Disease Pub Date : 2025-02-24 DOI: 10.1111/tid.70013

Andrew M Courtwright, Stacey Prenner, Jeffrey B Doyon, Tamara Claridge, Emily Blumberg, Christian A Bermudez, Maria M Crespo

{"title":"Lessons From the Utilization of Hepatitis B Virus Nucleic Acid Test Positive Donors for Hepatitis B Vaccinated Lung Transplant Candidates (INHIBITOR) Study.","authors":"Andrew M Courtwright, Stacey Prenner, Jeffrey B Doyon, Tamara Claridge, Emily Blumberg, Christian A Bermudez, Maria M Crespo","doi":"10.1111/tid.70013","DOIUrl":"https://doi.org/10.1111/tid.70013","url":null,"abstract":"Background: This was a single-center pilot study to determine the safety and efficacy of transplanting lungs from hepatitis B virus (HBV) nucleic acid positive (NAT+) donors to HBV vaccinated (sAb+) candidates. We report our study experience, including barriers to utilizing NAT+ donors.Methods: Primary candidate eligibility criteria included: HBV sAb+, < 70 years old, not on mechanical support, no liver fibrosis, normal esophageal motility, and cPRA < 60. Only brain-dead donors with no marginal characteristics or concurrent hepatitis C virus (HCV) were accepted. Recipients of HBV NAT+ organs would receive intravenous hepatitis B immunoglobulin as well as appropriate HBV antiviral therapy.Results: A total of 155 patients were screened for eligibility. Most (64.5%) were excluded because they were HBV sAb negative. Of the 25 eligible sAb+ candidates, 13 enrolled, and 6 were listed for HBV NAT+ organs. There were 16 donor offers, all of which were rejected because of quality or concurrent donor HCV infection. No other centers utilized these organs.Conclusions: Reduced enrollment related to strict eligibility criteria, few HBV immune candidates, and stringent requirements on HBV NAT+ donors were limiting factors. Further studies are needed to assess the safety and efficacy of HBV NAT+ donor lung transplants.","PeriodicalId":23318,"journal":{"name":"Transplant Infectious Disease","volume":" ","pages":"e70013"},"PeriodicalIF":2.6,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143493819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reduction in Length of Hospital Stays for Allogeneic Hematopoietic Stem-Cell Transplantation in the Letermovir Era.

IF 2.6 4区医学

Transplant Infectious Disease Pub Date : 2025-02-21 DOI: 10.1111/tid.70008

Hiroki Hosoi, Misato Tane, Tadashi Okamura, Shotaro Tabata, Ke Wan, Shogo Murata, Toshiki Mushino, Akinori Nishikawa, Takashi Sonoki

{"title":"Reduction in Length of Hospital Stays for Allogeneic Hematopoietic Stem-Cell Transplantation in the Letermovir Era.","authors":"Hiroki Hosoi, Misato Tane, Tadashi Okamura, Shotaro Tabata, Ke Wan, Shogo Murata, Toshiki Mushino, Akinori Nishikawa, Takashi Sonoki","doi":"10.1111/tid.70008","DOIUrl":"https://doi.org/10.1111/tid.70008","url":null,"abstract":"Background: In recent years, letermovir has been routinely used for cytomegalovirus (CMV) infection prophylaxis in patients receiving allogeneic hematopoietic stem-cell transplantation (HSCT). The reduction effect of letermovir on CMV infection rates and the impact on survival have been studied, but other potential benefits of letermovir remain underexplored.Methods: This retrospective study included patients who underwent first-time allogeneic HSCT between October 2013 and August 2023. We compared the length of hospital stay between eras before and after the introduction of letermovir (\"nonletermovir group\" and \"letermovir group,\" respectively). Secondary outcomes included clinically significant CMV infection rates and hospitalization costs.Results: A total of 59 patients were analyzed in the nonletermovir group and 65 patients in the letermovir group. The median length of hospital stay was 51 days in the nonletermovir group and 42 days in the letermovir group (p < 0.001). Among standard-risk disease patients, the letermovir group also had significantly shorter hospital stays (p = 0.0048). Additionally, the cumulative incidence of clinically significant CMV infection and grade II-IV acute graft-versus-host disease were both lower in the letermovir group. Hospitalization costs were not significantly different between the two groups.Conclusion: The length of hospital stays after HSCT was observed to be shorter following the introduction of letermovir in this study. This reduction in hospital stays did not decrease hospitalization costs in relation to allogeneic HSCT, but it may alleviate the burden on both patients and healthcare providers.","PeriodicalId":23318,"journal":{"name":"Transplant Infectious Disease","volume":" ","pages":"e70008"},"PeriodicalIF":2.6,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143473118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bridging the Gaps in CMV Management in Transplantation: Lessons From Resource-Limited Settings.

IF 2.6 4区医学

Transplant Infectious Disease Pub Date : 2025-02-21 DOI: 10.1111/tid.70009

Carlos A Gomez, Andre C Kalil

引用次数: 0

Microscopy: Not the Lost Art!

IF 2.6 4区医学

Transplant Infectious Disease Pub Date : 2025-02-21 DOI: 10.1111/tid.70007

Renjith Mathew Verghese, Gurpreet Singh Bhalla

引用次数: 0

Frailty and Infection in Solid-Organ Transplant Recipients.

IF 2.6 4区医学

Transplant Infectious Disease Pub Date : 2025-02-19 DOI: 10.1111/tid.14445

Sarah Taimur, Michael G Ison, John W Baddley, Maheen Z Abidi

{"title":"Frailty and Infection in Solid-Organ Transplant Recipients.","authors":"Sarah Taimur, Michael G Ison, John W Baddley, Maheen Z Abidi","doi":"10.1111/tid.14445","DOIUrl":"10.1111/tid.14445","url":null,"abstract":"Background: The association between frailty and infection in the transplant population is not well understood. Emerging data suggests that frailty at the time of transplant is associated with increased infection risk in liver and older kidney transplant recipients.Methods: The authors conducted a brief electronic survey of transplant infectious disease (TID) clinicians, to assess clinical practice trends on frailty assessment.Results: Among survey participants, only 40% reported a routine assessment of frailty in transplant candidates and recipients at their institutions, most commonly in liver transplant patients. The majority of respondents (77%) reported not being routinely involved in making clinical decisions utilizing frailty information. Seventy-one percent reported interest in the study of frailty in relation to infections in the transplant host.Conclusion: In this survey of TID clinicians, less than half reported a formal frailty assessment for candidates and recipients at their institutions. TID clinicians are mostly not involved in making clinical decisions related to frailty; however, the majority endorsed interest in frailty and infection research. We need future studies to enhance our understanding of the emerging data on the association between frailty and infection risk in the transplant host.","PeriodicalId":23318,"journal":{"name":"Transplant Infectious Disease","volume":" ","pages":"e14445"},"PeriodicalIF":2.6,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143450477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Seizures and Lung Lesions in a Solid Organ Transplant Recipient: Bringing Things Together.

IF 2.6 4区医学

Transplant Infectious Disease Pub Date : 2025-02-19 DOI: 10.1111/tid.14449

Matthew B Roberts, Julien Coussement, David Lebeaux, P Toby Coates, Wanessa Trindade Clemente

引用次数: 0

Evaluating Adverse Effects of Dapsone in Solid Organ Transplants.

IF 2.6 4区医学

Transplant Infectious Disease Pub Date : 2025-02-18 DOI: 10.1111/tid.70001

Kevin D He, Linh Nguyen, Maxwell Norris, Gregory Malat, Carson Shalaby, Chelsea Sammons, Emily Blumberg, Jennifer Trofe-Clark

引用次数: 0